
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc is positioned for significant growth in the upcoming quarters, supported by strong commercial momentum and an anticipated increase in sales due to a permanent J-code becoming effective on April 1, 2026. Management has provided guidance indicating first quarter 2026 product sales are expected to exceed $18 million, reflecting a remarkable sequential growth of over five-fold. The company's innovative technology platforms and active expansion efforts in treatment centers further enhance its potential for revenue acceleration and overall positive financial outlook.
Bears say
Precigen Inc. reported fourth-quarter sales of $3.4 million, significantly underperforming against the consensus estimate of $8.3 million. The company's net loss was $0.04 per diluted share, which, while slightly better than the expected loss of $0.08 per share, still reflects ongoing financial challenges. The substantial discrepancy between actual sales and expectations indicates potential difficulties in market acceptance or execution of its business strategy, contributing to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares